Overview
Opus Medical designs, manufactures, and distributes motion management devices for radiation therapy and medical imaging. Its products are patient-positioning and immobilization tools that keep patients still during treatments and scans, enabling precise radiation delivery and clearer images. The company differentiates itself with a strong academic foundation from Stanford University and the University of Sydney, local Australian manufacturing inside Cicada Innovations, and a disciplined, evidence-based approach to development and post-market support. Its goal is to broaden access to reliable motion management solutions for oncology and radiology worldwide, improving treatment accuracy and reducing patient risk.
Work here?Claim your company
Simplify's take
What believers are saying
- OpusWAVE Dual Sensor Imaging System won FDA substantial-equivalence clearance in July 2025.
- Breathe Well remains referenced in 2026 industry coverage and company materials.
- Existing regulatory approvals across the U.S., Europe, and Australia ease hospital purchasing.
What critics are saying
- PitchBook labeled Opus Medical out of business in March 2025.
- Opus Medical website now markets Nashville injury case management, signaling brand fragmentation.
- No recent financing, hiring, or clinical adoption evidence supports sustained motion-management revenue.
What makes Opus Medical unique
- Breathe Well targets respiratory motion during radiation using real-time patient biofeedback.
- Opus Medical holds FDA, CE, and TGA approvals for clinical use.
- Sydney manufacturing and Stanford-University of Sydney origins strengthen technical credibility.
Help us improve and share your feedback! Did you find this helpful?